Need professional-grade analysis? Visit stockanalysis.com
$379.28M
14.36
4,700
6.34%
Australian Clinical Labs Ltd (ACL) trades on Australian Securities Exchange in AUD. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at AUD2.07, down 0.96% from the previous close.
Over the past year, ACL has traded between a low of AUD1.94 and a high of AUD3.09. The stock has lost 27.5% over this period. It is currently 33.0% below its 52-week high.
Australian Clinical Labs Ltd has a market capitalization of $379.28M, with a price-to-earnings ratio of 14.36 and a dividend yield of 6.34%.
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. The company was incorporated in 2020 and is headquartered in Clayton, Australia.
Side-by-side comparison against top Healthcare peers.